Health Catalyst’s chief people officer sells $34,952 in stock

Linda Llewelyn, the Chief People Officer of Health Catalyst , Inc. (NASDAQ:HCAT), recently sold 6,441 shares of the company’s common stock. The transaction, which took place on February 18, 2025, was conducted at an average price of $5.4266 per share, totaling approximately $34,952. The sale comes as the stock trades near its 52-week low of $5.25, with InvestingPro analysis suggesting the company is slightly undervalued at its current market capitalization of $329 million. This sale was executed under a prearranged trading plan adopted on March 12, 2024, in accordance with Rule 10b5-1. Following this transaction, Llewelyn retains ownership of 85,819 shares in the company. With the company’s earnings report due on February 26, 2025, InvestingPro subscribers can access additional insights, including 6 more ProTips and comprehensive insider trading analysis, to make more informed investment decisions.

In other recent news, Health Catalyst Inc. has provided updates on its financial outlook and strategic initiatives. The company recently revised its revenue projections, indicating a reduction in its CY25 revenue growth by $19.9 million due to lower-than-expected revenue retention and bookings. Despite this, Health Catalyst maintains its target of achieving $39 million in adjusted EBITDA for CY25. The company has also announced the acquisition of Upfront Healthcare Services (NASDAQ:HCSG), expected to close in the first quarter of 2025, which aims to enhance its patient engagement capabilities.

Analysts have responded with mixed ratings. Piper Sandler reduced the price target for Health Catalyst to $8, maintaining an Overweight rating, while RBC Capital Markets adjusted their price target to $7, keeping a Sector Perform rating. Canaccord Genuity lowered its price target to $10 but sustained a Buy rating, highlighting the company’s potential to secure new platform clients. KeyBanc Capital Markets upgraded Health Catalyst to Overweight, setting a new price target of $9, citing the company’s favorable valuation and potential for growth.

The acquisition of Upfront Healthcare has been a focal point, with Health Catalyst aiming to expand its technology offerings and improve patient engagement. The company is also pursuing approximately 40 net new platform clients in 2025, an increase from 21 in 2024. These developments reflect Health Catalyst’s strategic efforts to strengthen its market position and achieve its financial targets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.